Following early uterine cancer with tiny cancer cells in nearby lymph nodes
Studies whether tiny cancer cells in lymph nodes near the uterus affect outlook.
Plain-language title generated from the registry record
Registry title: Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study
Key facts
- Where
- Vienna, AustriaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with low-risk endometrial (womb) cancer who had full surgery and have only tiny groups of tumor cells in the first lymph nodes near the tumor, and who need no treatment after surgery.
- Sex
- All sexes can join.
- Disease stage
- Low-risk endometrioid endometrial cancer, grade 1 or 2, FIGO 2009 stage IA (FIGO 2023 stages IA1 and IA2), without extensive LVSI (5 or more vessels involved). Focal LVSI (fewer than 5 vessels) is allowed. Only isolated tumor cells (≤ 0.2 mm or < 200 cells) in the sentinel lymph nodes.
- Earlier treatment
- Complete surgical staging with pelvic sentinel lymph node biopsy and ultrastaging. No treatment after surgery. No earlier chemotherapy before surgery.
Main reasons for not taking part
- Earlier chemotherapy before surgery
- Planned treatment after surgery
- Another cancer at the same time (except non-melanoma skin cancer)
- Larger tumor spread in the sentinel lymph nodes (micrometastasis or macrometastasis)
- Extensive LVSI (5 or more vessels involved)
Read by machine on 9 November 2026.
Where in Austria
- Medical University of ViennaVienna, AustriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mayo Clinic
- Trial code
- NCT06689956
- Record updated
- 19 February 2026
- Original description
This study evaluates whether isolated tumor cells in the first lymph nodes near the tumor can tell researchers something important about the future of patients with a certain type of endometrial (uterine) cancer.Read full original descriptionShow less
Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: a Prospective Multicenter Single-Arm Observational Study
This study evaluates whether isolated tumor cells in the first lymph nodes near the tumor can tell researchers something important about the future of patients with a certain type of endometrial (uterine) cancer.
Inclusion: Low-risk endometrial cancer, defined as endometrioid, grade 1 or 2, International Federation of Gynecology and Obstetrics (FIGO) 2009 stage IA (FIGO 2023 stages IA1 and IA2), without substantial/extensive LVSI (≥ 5 vessels involved) at final pathology. Patients with focal LVSI (< 5 vessels involved) will be included; Complete surgical staging, including pelvic sentinel lymph node (SLN) biopsy per National Comprehensive Cancer Network (NCCN) guidelines and ultrastaging; Extent of disease in SLN: ITC (defined as tumor cell aggregates ≤ 0.2 mm or < 200 cells); No adjuvant treatment after surgery; Research consent provided.
Exclusion: Prior neoadjuvant chemotherapy; Planning to receive adjuvant treatment; Presence of synchronous cancer (excluding non-melanoma skin cancer); Extent of disease in SLN: micrometastasis (> 0.2 to ≤ 2.0 mm) or macrometastasis (> 2.0 mm); Presence of substantial/extensive LVSI (≥ 5 vessels involved) at final pathology; Prior invasive cancer diagnosis within 5 years of study entry (excluding non-melanoma skin cancer).